Because SNPs are the most common type of genetic variation between human beings, these specific single base pair mutations can be ideal for the task of hunting for correlations between genotype and behavior or quality exhibited by a living organism. For this reason, SNP analysis represents one of many possible pathways to personalzied medicine. The use of SNP analysis has spread into numerous areas in recent years. But diagnostics and pharmacogenomics are the most promising applications, and Kalorama has followed developments in SNP analysis closely.

Kalorama Information's analyst Justin Saeks has taken a detailed look into the market for DNA Sequencing Equipment, as well as Gene Expression Profiling Systems. Now, in his report SNP Genotyping and Analysis Markets he looks at SNP analysis instruments, reagents, and related software and services, providing information critical to having an understanding of the business behind this new technology:

• Overview of SNPs, their Applications and Key SNP Analysis Methods
• Current Market Size and Estimates of Future Growth
• Impact of the GWAS 'First Round' on the Market
• Estimates of Revenues by Region (North America, Europe and ROW) and By Product Type (Consumable, Instruments, Software)
• Complete List of SNP-Related Deals Made Between Companies Since 2002
• Exhaustive Review of Products on the Market
• Market Share of Major Companies in SNP Analysis
• Discussion of GOLD Database Projects, Government Involvement and Funding
• Corporate Profiles
• Regulatory, Technology and Industry Trends as well as;
• Twelve Challenges the Market Faces and Eight Strategic Recommendations for Companies in the SNP Analysis Market

While the market is expected to create opportunities for growth, the SNP Genotyping and Analysis market is not without its challenges. The report tackles the following trends:

• Rapid Rate of Product Introductions
• Increased Multiplexing Creates Improved Products
• End-Users Attracted to Larger-Scale SNP Platforms
• Accelerating Discoveries Create Volatile Market
• Diagnostic Market Holds Obstacles For New Innovations
• Complexity of Biological Systems Requires Multiple Techniques
• Miniaturization of Equipment and Instruments

As with all Kalorama Information publications, SNP Genotyping and Analysis Markets is the result of a primary research effort. An analyst with experience following the biotech instrument industry researching all available sources and contacting industry experts and end users to obtain real market insights. Strategic Planners, Marketing Directors, Business Development Executives are among the individuals who will benefit from this resource.

Additional Information

New York, January 22, 2010 — A setback in the scientific basis for SNP (single nucleotide polymorphisms) analysis may turn out to be a blessing in disguise for makers of genotyping equipment, reagents and software, according to Kalorama Information. The medical market research publisher foresees double-digit growth in equipment sales, chemicals and software as more refined chips enter the market with the ability to measure rarer variants, as noted in SNP Genotyping and Analysis Markets.

SNP analysis has become an appealing method for identifying variations in DNA sequences for several reasons - SNPs are numerous, they account for over 80% of genetic variation in terms of quantity, they are stable through the generations, and they are easy to score. Also, the prices and the amount of content provided in SNP products have continued to improve, with the cost per genotype dropping on the order of ten-fold every two years since 2000.

While it was anticipated that the first round of Genome-wide association studies would result in the discovery of many disease associations for common ailments, the results were disappointing. The scientific community had relied on the assumption that common diseases were caused by common variants, which would be elucidated with SNP chips containing variants having 5% frequency. In the end, it appears that such studies need to look at rare variants occurring at around 1% frequency or less.

SNP genotyping can only analyze the variants that have been provided on the chips. So if only 5 to 10 variants were required for a given disease, as initially thought, fewer samples would need to be run per study. But if one hundred rare variants are cumulatively responsible for a given complex disease, as seems to be the case, then it is necessary to study more people to get enough data for statistical significance. This situation is an opportunity for new products that provide new capabilities.

“Despite the recent challenges, there is still money to be made in this market,” notes Bruce Carlson, publisher of Kalorama Information. “The need to find rarer variants will require new chips and more samples, which means greater use of the machines and chemicals involved in the analysis process.”

New microarray chips with more DNA probes capable of measuring more variants are just making their way onto the market. Kalorama anticipates they will lead to a new surge in projects, with growth approaching historical levels. The same instruments can still function with these chips.

Kalorama estimates annual growth of the SNP analysis technologies market at 10.1%, from $735 million in 2008 to about $1.3 billion in 2014. This growth will be driven mainly by whole-genome SNP analysis products in the near term. Longer term, the lower multiplexing products used in clinical trials will begin to account for more of the growth, as will the development of a side market in agriculture. Prices are expected to drop continuously, offsetting some of the growth from increased adoption.

Kalorama’s report, SNP Genotyping and Analysis Markets, takes a close look at this rapidly changing market, providing an in-depth market overview, market data and projections, product reviews, trends and challenges, strategic recommendations, and profiles of major competitors. It is available at:

http://www.kaloramainformation.com/redirect.asp?progid=76496&productid=2402105. About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. Follow us on Twitter and LinkedIn

Please direct all media inquiries to: Andrea Hiller, press@kaloramainformation.com; www.kaloramaInformation.com

Related Reports:

SNP and Whole Genome Sequencing Market Research Bundle
Apr 1, 2010 - KLI2614026 - $5,995.00

Lab Automation Markets, 2nd Edition (Systems, Key Companies, Forecasts and Trends)
Mar 1, 2010 - KLI2601060 - $3,995.00

DNA Sequencing Equipment and Services Markets, 2nd Edition
Aug 1, 2009 - KLI2122235 - $3,800.00

Pharmacodiagnostics and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key Players)
Apr 1, 2009 - KLI2128157 - $3,500.00

Liquid Chromatography Markets (LC, HPLC and UHPLC)
Mar 1, 2009 - KLI1430149 - $3,500.00

Key Genetic Technologies Market Research Bundle (SNPs, Gene Expression Profiling, DNA Sequencing and Analytical Chips)
Nov 1, 2008 - KLI1689637 - $7,995.00

SNP Genotyping and Analysis Markets
Jun 1, 2008 - KLI1430117 - $3,995.00

Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in 'Theranostics' and Personalized Medicine)
Jun 1, 2008 - KLI1646599 - $2,995.00

Gene Expression Profiling Markets
Jan 1, 2008 - KLI1430119 - $2,995.00

Analytical Chip Technology: U.S. Markets for Lab on a Chip, DNA/Gene, Protein, and other Microarrays, 3rd. Edition
Nov 1, 2007 - KLI1393085 - $1,995.00